Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I)
- PMID: 20354531
- PMCID: PMC2853094
- DOI: 10.1038/sj.bjc.6605605
Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I)
Abstract
Background: The first UKCCCR Anal Cancer Trial (1996) demonstrated the benefit of chemoradiation over radiotherapy (RT) alone for treating epidermoid anal cancer, and it became the standard treatment. Patients in this trial have now been followed up for a median of 13 years.
Methods: A total of 577 patients were randomised to receive RT alone or combined modality therapy using 5-fluorouracil and mitomycin C. All patients were scheduled to receive 45 Gy by external beam irradiation. Patients who responded to treatment were recommended to have boost RT, with either an iridium implant or external beam irradiation. Data on relapse and deaths were obtained until October 2007.
Results: Twelve years after treatment, for every 100 patients treated with chemoradiation, there are an expected 25.3 fewer patients with locoregional relapse (95% confidence interval (CI): 17.5-32.0 fewer) and 12.5 fewer anal cancer deaths (95% CI: 4.3-19.7 fewer), compared with 100 patients given RT alone. There was a 9.1% increase in non-anal cancer deaths in the first 5 years of chemoradiation (95% CI +3.6 to +14.6), which disappeared by 10 years.
Conclusions: The clear benefit of chemoradiation outweighs an early excess risk of non-anal cancer deaths, and can still be seen 12 years after treatment. Only 11 patients suffered a locoregional relapse as a first event after 5 years, which may influence the choice of end points in future studies.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/2853094/bin/6605605f1.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/2853094/bin/6605605f2.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/2853094/bin/6605605f3.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/2853094/bin/6605605f4.gif)
![Figure A1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/2853094/bin/6605605fa1.gif)
Similar articles
-
Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research.Lancet. 1996 Oct 19;348(9034):1049-54. Lancet. 1996. PMID: 8874455 Clinical Trial.
-
Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial.JAMA. 2008 Apr 23;299(16):1914-21. doi: 10.1001/jama.299.16.1914. JAMA. 2008. PMID: 18430910 Clinical Trial.
-
EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer.Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):119-26. doi: 10.1016/j.ijrobp.2007.12.012. Epub 2008 May 9. Int J Radiat Oncol Biol Phys. 2008. PMID: 18472366 Clinical Trial.
-
Anal carcinoma therapy: can we improve on 5-fluorouracil/mitomycin/radiotherapy?J Natl Compr Canc Netw. 2010 Jan;8(1):135-44. doi: 10.6004/jnccn.2010.0009. J Natl Compr Canc Netw. 2010. PMID: 20064295 Review.
-
[Chemoradiotherapy in treatment of cancer of the anal canal].Cancer Radiother. 1998 Dec;2(6):708-12. doi: 10.1016/s1278-3218(99)80012-2. Cancer Radiother. 1998. PMID: 9922777 Review. French.
Cited by
-
Radiation Therapy in the Management of Extensive Giant Condyloma Acuminata With Rectal Involvement: A Case Report.Cureus. 2024 Mar 25;16(3):e56882. doi: 10.7759/cureus.56882. eCollection 2024 Mar. Cureus. 2024. PMID: 38659525 Free PMC article.
-
Outcomes of patients with anal cancer treated with definitive chemoradiation: A single centre experience.Ecancermedicalscience. 2024 Jan 15;18:1655. doi: 10.3332/ecancer.2024.1655. eCollection 2024. Ecancermedicalscience. 2024. PMID: 38425766 Free PMC article.
-
Recent Advances in the Management of Anal Cancer.Healthcare (Basel). 2023 Nov 21;11(23):3010. doi: 10.3390/healthcare11233010. Healthcare (Basel). 2023. PMID: 38063578 Free PMC article. Review.
-
Risk-adjusted chemoradiation according to human papilloma viral status for anal cancer: a pilot study.Front Oncol. 2023 Jun 29;13:1183854. doi: 10.3389/fonc.2023.1183854. eCollection 2023. Front Oncol. 2023. PMID: 37456246 Free PMC article.
-
Definitive S-1/mitomycin-C chemoradiotherapy for stage II/III anal canal squamous cell carcinoma: a phase I/II dose-finding and single-arm confirmatory study (JCOG0903).Int J Clin Oncol. 2023 Aug;28(8):1063-1072. doi: 10.1007/s10147-023-02361-7. Epub 2023 Jun 7. Int J Clin Oncol. 2023. PMID: 37286878 Clinical Trial.
References
-
- Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson III AB, Thomas Jr CR, Mayer RJ, Haddock MG, Rich TA, Willett C (2008) Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 299: 1914–1921 - PubMed
-
- Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, Peiffert D, van Glabbeke M, Pierart M (1997) Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 15: 2040–2049 - PubMed
-
- Cancer Research UK (2008) Risks and causes of anal cancer. http://www.cancerhelp.org.uk/type/anal-cancer/about/risks-and-causes-of-.... Accessed on 19 June, 2009. Ref Type: Electronic Citation
-
- Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR, for the Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358: 36–46 - PubMed
-
- Daher IN, Yeh ET (2008) Vascular complications of selected cancer therapies. Nat Clin Pract Cardiovasc Med 5: 797–805 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical